J. Ware

发表

Membrane transporters in drug development

M. Niemi, Y. Sugiyama, K. Giacomini, 2010, Nature Reviews Drug Discovery.

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

J. Ware, J. Spoerke, P. Workman, 2014, Clinical Cancer Research.

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

Joe Palandra, Bradley L Urquhart, R. Kim, 2008, Pharmacogenetics and genomics.

Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein.

J. Ware, F. Sellke, M. Ruel, 2002, The Journal of thoracic and cardiovascular surgery.

Therapeutic angiogenesis in cardiovascular disease

J. Ware, M. Simons, J. Ware, 2003, Nature Reviews Drug Discovery.

Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: possible role in allergic reactions.

J. Ware, B. Martin, L. Pohl, 1998, Chemical research in toxicology.

Food for starving hearts

J. Ware, M. Simons, J. Ware, 1996, Nature Medicine.

Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys.

J. Ware, K. Hotzel, K. Setchell, 2012, Toxicological sciences : an official journal of the Society of Toxicology.

Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2.

R. Kim, J. Ware, H. E. Meyer zu Schwabedissen, 2009, Molecular pharmaceutics.

Cyclooxygenase inhibitors increase Na-K-2Cl cotransporter abundance in thick ascending limb of Henle's loop.

J. Ware, P. Fernández-Llama, S. Nielsen, 1999, American journal of physiology. Renal physiology.

Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors

J. Ware, Diansong Zhou, V. Pilla Reddy, 2021, Cancer Chemotherapy and Pharmacology.

Development of in vitro methods to predict induction of CYP1A2 and CYP3A4 in humans.

J. Ware, R. Voorman, T. G. Brayman, 2007, Assay and drug development technologies.

Cellular distribution of N-acetyltransferase activity in the rat small intestine.

J. Ware, T. Reilly, C. K. Svensson, 1998, Biochemical pharmacology.

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

G. Demetri, J. Ware, P. LoRusso, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

J. Ware, J. Bendell, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

223 POSTER Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation

G. Demetri, J. Ware, P. LoRusso, 2008 .

Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy

J. Ware, E. Reyner, M. Kågedal, 2019, Clinical and translational science.

A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).

L. Pusztai, J. Baselga, T. Wilson, 2016 .

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

J. Ware, K. Morrissey, L. Salphati, 2019, British journal of clinical pharmacology.

Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics

John D. Davis, J. Ware, K. Morrissey, 2017, CPT: pharmacometrics & systems pharmacology.

A solid phase extraction-liquid chromatographic-tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development.

J. Ware, S. Reuschel, M. Meng, 2012, Journal of pharmaceutical and biomedical analysis.

A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.

J. Ware, J. Spoerke, J. Schellens, 2017, The oncologist.

Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer

E. Winer, J. Baselga, T. Wilson, 2015 .

A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

G. Demetri, J. Ware, G. Shapiro, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative systems pharmacology model‐based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors

Christina M. Friedrich, J. Ware, K. Gadkar, 2021, CPT: pharmacometrics & systems pharmacology.

Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects

J. Ware, H. Tomkinson, X. Pepin, 2022, British journal of clinical pharmacology.

Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis.

J. Ware, P. LoRusso, W. Fairbrother, 2012, Toxicological sciences : an official journal of the Society of Toxicology.

A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma.

J. Ware, J. Bendell, H. Burris, 2010 .

Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW).

G. Jayson, J. Ware, J. Soria, 2011 .

Disposition of Procainamide in Patients with Chronic Congestive Heart Failure Receiving Medical Therapy

J. Ware, M. Rudis, B. Zarowitz, 1996, Journal of clinical pharmacology.

Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans

J. Ware, L. Salphati, Shuguang Ma, 2021, Xenobiotica; the fate of foreign compounds in biological systems.

Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0152 in human plasma using solid-phase extraction.

J. Ware, H. Wong, C. Hop, 2013, Biomedical chromatography : BMC.

Angiogenesis and cardiovascular disease

J. Ware, M. Simons, 1999 .

Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach

J. Ware, F. Bellanti, H. Edlund, 2021, British Journal of Clinical Pharmacology.

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors

J. Ware, D. Ramies, H. Tomkinson, 2022, Clinical pharmacology in drug development.

Abstract 2194: Preclinical pharmacological profiling of ACP-5862, the major metabolite of the covalent BTK inhibitor acalabrutinib, displays intrinsic BTK inhibitory activity

J. Ware, J. G. Slatter, A. Kaptein, 2019, Experimental and Molecular Therapeutics.

Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).

Zhaoyang Wen, Brigitte Maurer, Vickie Tsui, 2012, Journal of medicinal chemistry.

A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

Yulei N. Wang, J. Ware, J. Spoerke, 2016, Cancer.

Simultaneous determination of itraconazole, hydroxy itraconazole, keto itraconazole and N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry.

J. Ware, Yuan Chen, J. Mao, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria

L. Benet, J. Ware, L. Salphati, 2014, The AAPS Journal.

Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.

J. Ware, L. Salphati, B. Dean, 2013, Molecular pharmaceutics.

Therapeutic Angiogenesis for Ischemic Vascular Disease

J. Ware, J. Ware, J. Singh, 2005 .

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

M. Zauderer, R. Yeh, J. Ware, 2016, Clinical Cancer Research.

18. Future Perspectives

T. Ishikawa, J. Ware, 2013 .

EXPRESSION AND FUNCTION OF ABCB1 AND ABCG2 IN HUMAN PLACENTAL TISSUE

Timothy S Tracy, J. Ware, T. Tracy, 2005, Drug Metabolism and Disposition.

Effects of An E-cadherin-Derived Peptide on the Gene Expression of Caco-2 Cells

J. Ware, J. Fostel, W. Mattes, 2004, Pharmaceutical Research.

Covalent Binding of the Nitroso Metabolite of Sulfamethoxazole Is Important in Induction of Drug-Specific T-Cell Responses in Vivo

J. Ware, D. Petersen, C. Ju, 2008, Molecular Pharmacology.

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

A. Ravaud, Yulei N. Wang, R. Motzer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

H. Groen, J. Ware, K. Morrissey, 2017, European Journal of Cancer.

A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

J. Ware, N. Tunariu, H. Koeppen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).

J. Ware, J. Soria, R. Brachmann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma.

J. Ware, J. McKnight, B. Dean, 2014, Journal of pharmaceutical and biomedical analysis.

Curcumin Inhibits the Activity of ABCG2/BCRP1, a Multidrug Resistance-Linked ABC Drug Transporter in Mice

J. Ware, S. Ambudkar, S. Shukla, 2009, Pharmaceutical Research.

Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design

Caroline A. Lee, J. Polli, J. Ware, 2015, Drug Metabolism and Disposition.

Mechanisms and Genetics of Drug Transport

Shiew-Mei Huang, J. Ware, Lei Zhang, 2013 .

Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin

R. Kim, J. Ware, J. Stock, 2008, Molecular Pharmacology.

Cyclooxygenase inhibitors increase Na-K-2Cl cotransporter abundance in thick ascending limb of Henle's loop.

J. Ware, P. Fernández-Llama, S. Nielsen, 1999, The American journal of physiology.

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor

M. Belvin, J. Ware, K. Hoeflich, 2012, Clinical Cancer Research.

Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.

J. Ware, R. Sutton, L. Salphati, 2013, Molecular pharmaceutics.

1205 A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours

G. Demetri, J. Ware, P. LoRusso, 2009 .

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors

G. Demetri, J. Ware, P. LoRusso, 2009 .

Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium

K. Brouwer, R. Evers, J. Polli, 2018, Clinical pharmacology and therapeutics.

Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile.

J. Ware, Charles G. Knutson, M. Grillo, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Mechanistic studies on the bioactivation of diclofenac: identification of diclofenac-S-acyl-glutathione in vitro in incubations with rat and human hepatocytes.

J. Ware, Chunze Li, Charles G. Knutson, 2003, Chemical research in toxicology.

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH‐Dependent Solubility the Achilles Heel of Targeted Therapy?

J. Ware, A. Frymoyer, N. Budha, 2012, Clinical pharmacology and therapeutics.

ITC Commentary on Metformin Clinical Drug–Drug Interaction Study Design That Enables an Efficacy‐ and Safety‐Based Dose Adjustment Decision

K. Giacomini, X. Chu, Caroline A. Lee, 2018, Clinical pharmacology and therapeutics.

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

J. Ware, Diansong Zhou, J. G. Slatter, 2019, CPT: pharmacometrics & systems pharmacology.

Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies

J. Ware, H. Edlund, H. Tomkinson, 2021, British journal of clinical pharmacology.

Pharmacogenomics in the age of personalized medicine.

Leslie J Dickmann, J. Ware, L. Dickmann, 2016, Drug discovery today. Technologies.

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

J. Baselga, T. Wilson, J. Ware, 2017, Cancer discovery.

Angiogenesis in ischemic heart disease

J. Ware, M. Simons, J. Ware, 1997, Nature Medicine.

Response to “Drug Interactions Produced by Proton Pump Inhibitors: Not Simply a pH Effect”

L. Benet, J. Ware, N. Budha, 2013, Clinical pharmacology and therapeutics.

Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Sandra, J. Baselga, T. Wilson, 2017 .

Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects

J. Ware, E. Choo, Kenta Yoshida, 2018, Journal of clinical pharmacology.

Breast Cancer Resistance Protein (BCRP/ABCG2) is a Major Determinant of Sulfasalazine Absorption and Elimination in the Mouse

J. Ware, L. Yu, Anis A. Khan, 2006, Molecular pharmaceutics.

Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis

R. Kim, J. Ware, D. Finkelstein, 2011, Hepatology.

Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.

Leslie Z Benet, Brian Dean, L. Benet, 2013, Molecular pharmaceutics.

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

L. Staudt, W. Wilson, J. Vose, 2019, Blood.

A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941.

J. Ware, D. Sarker, R. Kristeleit, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy

J. Ware, Buyun Chen, Li Zhou, 2022, British journal of clinical pharmacology.

Inhibition of N‐Acetylation of Procainamide and Renal Clearance of N‐Acetylprocainamide by Para‐Aminobenzoic Acid in Humans

J. Ware, M. Rudis, B. Zarowitz, 1995, Journal of clinical pharmacology.

New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS)

J. Ware, D. Ramies, H. Tomkinson, 2021, Blood.

Gamma-glutamyltranspeptidase-mediated degradation of diclofenac-S-acyl-glutathione in vitro and in vivo in rat.

L. Benet, J. Ware, Charles G. Knutson, 2008, Chemical Research in Toxicology.

Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine.

J. Ware, C. K. Svensson, 1996, Biochemical pharmacology.

Dextromethorphan Pretreatment Induces Antipyrine Clearance in the Rat

J. Ware, C. K. Svensson, 1988, Pharmaceutical Research.

Abstract B137: Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC‐0980: Initial phase I evaluation

G. Jayson, J. Ware, J. Soria, 2009 .

Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.

J. Ware, L. Yu, Anis A. Khan, 2006 .

Breast Cancer Resistance Protein Substrate and Inhibition Evaluation: Why, When, and How?

J. Ware, B. Urquhart, Y. Sugiyama, 2014, Drug Metabolism and Disposition.

A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).

A. Ravaud, T. Powles, R. Motzer, 2014 .

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

Yuichi Sugiyama, Miyuki Kimura, Hiroyuki Kusuhara, 2008, Clinical pharmacology and therapeutics.

Evaluation of Metabolism and Disposition of GDC-0152 in Rats Using 14C Labeling Strategy at Two Different Positions: A Novel Formation of Hippuric Acid from 4-Phenyl-5-Amino-1,2,3-Thiadiazole

J. Ware, J. Lyssikatos, H. Wong, 2013, Drug Metabolism and Disposition.

J. Ware, R. Eversole, S. Vonderfecht, 2004, Toxicologic pathology.

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

H. Kusuhara, Y. Sugiyama, J. Ware, 2008, Clinical pharmacology and therapeutics.

Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design

Caroline A. Lee, J. Polli, J. Ware, 2015, Drug Metabolism and Disposition.

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

J. Baselga, J. Ware, D. Juric, 2017, Cancer discovery.

Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS.

J. Ware, J. McKnight, B. Dean, 2016, Journal of pharmaceutical and biomedical analysis.

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

J. Ware, Diansong Zhou, J. G. Slatter, 2019, CPT: pharmacometrics & systems pharmacology.